A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Sponsored by ACADIA Pharmaceuticals Inc.
About this trial
Last updated 6 years ago
Study ID
ACP-103-015
Status
Completed
Type
Interventional
Phase
Phase 3
Placebo
No
Accepting
40+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 7 years ago
What is this trial about?
To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's
disease psychosis.
What are the participation requirements?
Inclusion Criteria
- Subject has completed the treatment period of a previous blinded study of pimavanserin
- The subject is willing and able to provide consent
- Caregiver is willing and able to accompany the subject to all visits
Exclusion Criteria
- Subject has current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder
- Subject is judged by the Investigator to be inappropriate for the study